Literature DB >> 21619552

The significance of MGMT protein detection in evaluation of osteosarcoma necrosis rate after cisplatin chemotherapy.

Qiu Cui1, Dingfeng Li, Cheng Liu, Jun Guo, Shubin Liu, Yaosheng Liu, Xiaohong Wang, Yanjun Zeng.   

Abstract

The aim of this article was to investigate the correlation between expression of O(6)-methylguanine-DNA methyltransferase (MGMT) in osteosarcoma and the curative effect of alkylating agent (Cis-diaminodichloroplatinum, CDDP). 42 male patients and 34 female patients with a median age of 17 years (9 to 43 years) were eligible for this study. According to histopathological types, there were 3 cases of telangiectatic osteogenic sarcoma, 22 cases of osteoblastic, 11 cases of chondroblastic and 16 cases of fibroblastic sarcoma. Immunohistochemical method was used to detect the expression of MGMT protein. The correlations between MGMT expression and the curative effect of CDDP on osteosarcoma have been investigated. It was shown by immunohistochemical staining that among 76 osteosarcoma biopsy specimens, 52 (68%) cases were positive, 27 (35%) cases were weak positive, 18 (24%), cases were moderate positive, and 7 (9%) cases were strong positive. There were no significant differences in MGMT expression among different pathological types of tumors (p>0.5). After CDDP chemotherapy, among pathologic specimens in which MGMT expression was positive, necrosis rates were as follows: grade I, 5 cases (38%); grade II, 7 cases (25%); grade III, 15 cases (21%); grade IV, 2 cases (23%). Osteosarcoma necrosis rate was low when the expression of MGMT protein was positive, whereas necrosis rate was high when there was a low level of MGMT expression (p<0.01). There was a significant negative correlation between the level of MGMT expression in osteosarcoma tissue and osteosarcoma necrosis rate after cisplatin chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21619552      PMCID: PMC4362593          DOI: 10.17305/bjbms.2011.2585

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  10 in total

Review 1.  Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy.

Authors:  Ami Sabharwal; Mark R Middleton
Journal:  Curr Opin Pharmacol       Date:  2006-06-13       Impact factor: 5.547

2.  O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts.

Authors:  J Mattern; U Eichhorn; B Kaina; M Volm
Journal:  Int J Cancer       Date:  1998-09-11       Impact factor: 7.396

3.  Human osteosarcoma xenografts and their sensitivity to chemotherapy.

Authors:  Skjalg Bruheim; Oyvind S Bruland; Knut Breistol; Gunhild M Maelandsmo; Oystein Fodstad
Journal:  Pathol Oncol Res       Date:  2004-09-25       Impact factor: 3.201

Review 4.  MGMT hypermethylation: a prognostic foe, a predictive friend.

Authors:  Filipe V Jacinto; Manel Esteller
Journal:  DNA Repair (Amst)       Date:  2007-05-07

5.  Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy.

Authors:  G Rosen; B Caparros; A G Huvos; C Kosloff; A Nirenberg; A Cacavio; R C Marcove; J M Lane; B Mehta; C Urban
Journal:  Cancer       Date:  1982-03-15       Impact factor: 6.860

6.  Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma.

Authors:  Verena Voelter; Annie-Claire Diserens; Alexandre Moulin; Georg Nagel; Pu Yan; Eugenia Migliavacca; Donata Rimoldi; Marie-France Hamou; Bernd Kaina; Serge Leyvraz; Monika E Hegi
Journal:  Int J Cancer       Date:  2008-09-01       Impact factor: 7.396

7.  O6-methylguanine-DNA methyltransferase activity in breast and brain tumors.

Authors:  I Preuss; I Eberhagen; S Haas; R H Eibl; M Kaufmann; G von Minckwitz; B Kaina
Journal:  Int J Cancer       Date:  1995-05-04       Impact factor: 7.396

Review 8.  Potential and cytotoxicity of cis-platinum complex with anti-tumor activity in combination therapy.

Authors:  John W Ho
Journal:  Recent Pat Anticancer Drug Discov       Date:  2006-01       Impact factor: 4.169

Review 9.  O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy.

Authors:  Barbara Verbeek; Thomas D Southgate; David E Gilham; Geoffrey P Margison
Journal:  Br Med Bull       Date:  2008-02-01       Impact factor: 4.291

Review 10.  DNA repair pathways as targets for cancer therapy.

Authors:  Thomas Helleday; Eva Petermann; Cecilia Lundin; Ben Hodgson; Ricky A Sharma
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

  10 in total
  1 in total

1.  Necrosis of osteosarcoma cells induces the production and release of high-mobility group box 1 protein.

Authors:  Jiyu Yang; Zhiqiang Ma; Yanlong Wang; Zengkun Wang; Youwei Tian; Yingchao Du; Wei Bian; Yongfu Duan; Jianyu Liu
Journal:  Exp Ther Med       Date:  2017-11-01       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.